Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib

Melanoma Research

Volumn 24, Issue 2, 2014, Pages 172-176

  Liebner, David A ^a   Walston, Steven A ^a   Cavaliere, Robert ^a   Powers, Ciaran J ^a   Sauvageau, Eric ^a   Lehman, Norman L ^a   Wayne Slone, Hasel ^a   Meng, Xu Welliver ^a   Xia, Fen ^a   Kendra, Kari L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

BRAF inhibition; Brain metastases; Melanoma; Radiation necrosis; Radiation therapy; Stereotactic radiosurgery; Vemurafenib

Indexed keywords

VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BRAF GENE; CANCER PATIENT; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG WITHDRAWAL; HUMAN; MALE; MELANOMA; MELANOMA METASTASIS; MUTANT; ONCOGENE; PATIENT MONITORING; PRIORITY JOURNAL; RADIATION NECROSIS; STEREOTACTIC RADIOSURGERY; TREATMENT PLANNING; TREATMENT RESPONSE; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; FEMALE; MUTATION; NECROSIS; PATHOLOGY; RADIATION DOSE; RADIATION INJURIES; RADIATION RESPONSE; SKIN NEOPLASMS; YOUNG ADULT;

ADULT; CENTRAL NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MUTATION; NECROSIS; RADIATION DOSAGE; RADIATION INJURIES; SKIN NEOPLASMS; SULFONAMIDES; YOUNG ADULT;

EID: 84896398934     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000044     Document Type: Article

References (20)

1. Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res 2012; 22: 177-183.
2. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-1300.
3. Jahanshahi P, Nasr N, Unger K, Batouli A, Gagnon GJ. Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. Front Oncol 2012; 2: 167.
4. Bernard ME, Wegner RE, Reineman K, Heron DE, Kirkwood J, Burton SA, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. J Cancer Res Ther 2012; 8: 215-221.
5. Choi CY, Chang SD, Gibbs IC, Adler JR, Harsh GRt, Lieberson RE, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys 2012; 84: 336-342.
6. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.
7. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365: 2439-2441.
8. Dummer R, Rinderknecht J, Goldinger SM, Wagner I, Mitchell L, Veronese ML, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011; 29 (15S): 8548.
9. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 2013; 31: e40-e43.
10. Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013; 23: 175-178.
11. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, et al. Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 2012; 87: 976-981.
12. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013; 31: e220-e222.
13. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31: e283-e287.
14. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113: 411-416.
15. Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 2009; 15: 3050-3057.
16. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 98: 394-399.
17. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767-1774.
18. Siu A, Wind JJ, Iorgulescu JB, Chan TA, Yamada Y, Sherman JH. Radiation necrosis following treatment of high grade glioma - a review of the literature and current understanding. Acta Neurochir (Wien) 2012; 154: 191-201.
19. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.
20. Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, et al. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 2011; 103: 683-691.